Q3 2025 SOPHiA GENETICS SA Earnings Call Transcript
Key Points
- Sophia Genetics SA (SOPH) reported a 23% year-over-year revenue growth in Q3 2025, marking the third consecutive quarter of accelerated growth.
- The company raised its 2025 revenue guidance to $75 million to $77 million, reflecting strong business momentum.
- Sophia Genetics SA (SOPH) signed 31 new customers in Q3, bringing the total new customers for 2025 to 94, surpassing the previous year's total.
- The company expanded its footprint in several top-ranked institutions, including Gustave Roussy in Paris and Institut Paoli-Calmettes in Marseille.
- Sophia Genetics SA (SOPH) maintained a strong adjusted gross margin of 73.1% despite a substantial increase in data processing volume.
- Sophia Genetics SA (SOPH) experienced a 54% share price depreciation, resulting in higher Swiss social charges on share-based compensation.
- The company faced adverse foreign exchange movements, impacting reported operating expenses due to the strengthening of the Swiss franc.
- Legal expenses increased by approximately $600,000 due to a patent infringement lawsuit filed by Guardant Health.
- Total cash burn increased by 36.5% year-over-year, reaching $13.1 million in Q3 2025.
- Sophia Genetics SA (SOPH) reported an adjusted EBITDA loss of $10.2 million, up 8% from the prior year.
Good morning. My name is Kelsey, and I'll be your conference operator today. At this time, I would like to welcome everyone to the SOPHiA GENETICS third quarter 2025 earnings conference call.
Kellen Sanger, SOPHiA GENETICS Head of Strategy, Investor Relations, you may begin.
Thank you, and good morning, everyone. Welcome to the SOPHiA GENETICS third quarter 2025 earnings conference call. Joining me today to discuss the results are Dr. Jurgi Camblong, our Co-Founder and Chief Executive Officer; Ross Muken, our Company President; and George Cardoza, our Chief Financial Officer.
I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities law. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated, and you should not place undue reliance on forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
